Drug intelligence / Profile preview

VDN 0400

Development stage: Preclinical
Lead developer: Vedana Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

VDN 0400 is a monoclonal antibody currently in the discovery stage for the prevention of migraine. Developed by Vedana Therapeutics, the candidate targets an undisclosed biological pathway involved in migraine pathogenesis. As a monoclonal antibody, it is designed for high specificity, though its exact molecular target and mechanism of action remain proprietary as of its discovery-stage status.

Beyond the preview

Go deeper on VDN 0400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDN 0400.

Explore the full profile